|
CNI Movement Disorders Center
Research & Outcomes
Huntington's Disease Studies
STUDY: Reach2HD
Primary Investigator: Vicki Segro, MSN, C-ANP and Rajeev Kumar, MD (physician oversight)
Coordinator: Diane Erickson, RN, CCRC
Contact: 303-762-6674
e-mail: derickson@thecni.org
Site: CNI, 701 E. Hampden Ave. Suite 510, Englewood, Colorado 80113
PURPOSE: Reach2HD will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a day compared to a placebo over six months. The trial will also measure whether there is an effect on cognitive abilities as well as other HD symptoms including motor and overall functioning of individuals with HD.
ELIGIBILITY:
To be eligible for participation in the study, patients must:
- Have early to mid-stage Huntington disease
- Age 25 and older
- Have a study partner who can come to some of the research visits
- Have 8 clinic visits over 6 months and 3-4 visits to the study ophthalmologist located in Cherry Creek
________________________________________________________________
STUDY: Predict-HD
Primary Investigator: Rajeev Kumar, MD
Coordinator: Diane Erickson, RN, CCRC
Contact: 303-762-6674
e-mail: derickson@thecni.org
Site: CNI, 701 E. Hampden Ave. Suite 510, Englewood, Colorado 80113
PURPOSE: This long-term, observational study will look at individuals who have undergone Huntington disease genetic testing and are either gene positive or negative and are pre-symptomatic. Visits occur 1 time a year with telephone contact between visits. Visits include: movement assessment by Dr. Kumar, a blood draw, completion of self-assessments and assessments by companion, cognitive testing, MRI of brain at specific visits, review of medications and blood pressure.
ELIGIBILITY:
- 18 years and older
- Gene positive or negative for Huntington disease
- Able to have an MRI of the brain
- Certain medications not allowed
- Commitment of “companion” to attend visits and provide information
>>Parkinson's Disease Studies
>>Progressive Supranuclear Palsy Studies
|
